Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Baxter
Merck
Moodys
Boehringer Ingelheim

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENDEKA

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for BENDEKA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03406156 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Recruiting AbbVie Phase 3 2018-08-10 A study in previously untreated Chronic Lymphocytic Leukemia to evaluate alternate administration strategies for induction therapy (debulking) with obinutuzumab or obinutuzumab/bendamustine prior to combination therapy with obinutuzumab and venetoclax.
NCT03623373 Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Not yet recruiting Acerta Pharma BV Phase 1 2018-10-31 This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab and cytarabine and rituximab (BR/CR) in subjects with treatment naïve mantle cell lymphoma (MCL), as a preparation for a larger cooperative group trial with the goal of achieving a standard induction regimen for MCL in transplant eligible patients. The investigators hypothesize that the addition of acalabrutinib to BR/CR regimen will prove safe and increase the complete response (CR) rate as well as minimal residual disease (MRD) negativity pre-transplant, thus improving clinical outcomes.
NCT03623373 Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Not yet recruiting Washington University School of Medicine Phase 1 2018-10-31 This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab and cytarabine and rituximab (BR/CR) in subjects with treatment naïve mantle cell lymphoma (MCL), as a preparation for a larger cooperative group trial with the goal of achieving a standard induction regimen for MCL in transplant eligible patients. The investigators hypothesize that the addition of acalabrutinib to BR/CR regimen will prove safe and increase the complete response (CR) rate as well as minimal residual disease (MRD) negativity pre-transplant, thus improving clinical outcomes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BENDEKA

Condition Name

Condition Name for BENDEKA
Intervention Trials
Mantle Cell Lymphoma 2
Immunoproliferative Disorders 1
Allogeneic Hematopoietic Stem Cell Transplant Recipient 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for BENDEKA
Intervention Trials
Lymphoma 4
Leukemia 2
Lymphoma, Mantle-Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for BENDEKA

Trials by Country

Trials by Country for BENDEKA
Location Trials
United States 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for BENDEKA
Location Trials
Missouri 3
Washington 2
Texas 2
Colorado 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for BENDEKA

Clinical Trial Phase

Clinical Trial Phase for BENDEKA
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for BENDEKA
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for BENDEKA

Sponsor Name

Sponsor Name for BENDEKA
Sponsor Trials
National Cancer Institute (NCI) 3
Washington University School of Medicine 2
AbbVie 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for BENDEKA
Sponsor Trials
Other 7
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Merck
Johnson and Johnson
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.